Share

April 2016; 6 (2) Editorial

Long-term registries

Answering tough questions with big data?

Robert J. Fox, Gary Cutter
First published March 21, 2016, DOI: https://doi.org/10.1212/CPJ.0000000000000226
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
88

Share

Article Information

vol. 6 no. 2 97-99
DOI: 
https://doi.org/10.1212/CPJ.0000000000000226
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published March 21, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Robert J. Fox, MD and
    2. Gary Cutter, PhD
  1. Robert J. Fox, MD and
    2. Scientific Advisory Boards:

    1. Biogen Idec, Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board, Neurology Editorial Board, Multiple Sclerosis Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. Multiple Sclerosis and Related Disorders, Demos Medical, 2013

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Actelion, Biogen Idec, MedDay, Novartis, Mallinckrodt, Teva, and XenoPort

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research grant from Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society, RC 1004-A-5, 2010- 2013; RG 4778-A-6, 2013-2018; NIH 1U01NS082329-01A1, 2013- 2018; Consortium of MS Centers

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Gary Cutter, PhD
    3. Scientific Advisory Boards:

    1. Participation of Data and Safety Monitoring Committees: Apotek Biogen-Idec Cleveland Clinic(Vivus) Glaxo Smith Klein Pharmaceuticals Gilead Pharmaceuticals Modigenetech/Prolor Merck/Ono Pharmaceuticals Merck Merck/Pfizer Neuren Sanofi-Aventis Teva University of Kansas NHLBI (Protocol Review Committee) NINDS NICHD (OPRU oversight committee)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Consortium of MS Centers, speaker honoraria; (2) Teva, Speaker honoraria

    Editorial Boards:

    1. (1) Multiple Sclerosis, Editorial Board, 2010-present (2) JASN, 2013- present, statistical consulting reviewer (3) Alzheimers & Dementia: Translational Research & Clinical Interventions

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Employed by the University of Alabama at Birmingham; (2) President of Pythagoras, Inc. a private consulting company located in Birmingham AL.

    Consultancies:

    1. Consortium of MS Centers (grant) Genentech Genzyme Jannsen Pharmaceuticals Klein-Buendel Incorporated Medimmune Novartis Nivalis Therapeutics Opexa Therapeutics Receptos Roche Somahlution EMD Serono Spiniflex Pharmaceuticals Teva pharmaceuticals Transparency Life Sciences

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) NARCOMS MS Patient Registry

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. No direct grants, but work on studies funded to the Consortium of MS Centers subcontracted for analysis of NARCOMS Registry.

    Research Support, Government Entities:

    1. ACTIVE U01 NS 042685 (Cutter) 09/23/2005 ? 08/31/2015 NIH/NINDS Thymectomy Plus Prednisone vs. Prednisone Alone in NonThymomatous Myasthenia Gravis This multinational clinical trial aims to assess the utility of thymectomy in treating nonthymomatous Myasthenia Gravis patients comparing surgery plus medications versus medications alone. P30-AI 027767 (Saag, M.) 06/01/2014 ? 05/31/2019 NIH/NIAID UAB Center for Aids Research This CFAR is organized as a partnership between the University of Alabama at Birmingham and the Southern Research Institute. The primary purpose of this partnership is to generate interdisciplinary AIDS research efforts. This Center is responsible for planning, evaluating, managing and documenting a broad array of research activities within two institutions. Particular emphasis is placed upon linking clinical and basic science studies through the use of shared facilities and to translate as quickly as possible fundamental knowledge about AIDS and its related disorders into clinical treatment and prevention programs. U01-HL 119242 (Cutter) 09/01/2014 ? 05/31/2020 NIH/NHLBI Chronic Hypertension and Pregnancy (CHAP): Data Coordinating Center We propose a large pragmatic multi-center randomized trial of pregnant women with mild chronic hypertension to evaluate the benefits and harms of antihypertensive therapy to a goal <140/90 mmHg (as recommended for the general population in the US) compared with ACOG's current policy of expectant management of mild chronic hypertension in pregnancy. The trial will be conducted in 12 experienced research-oriented Ob/Gyn departments (including 25 clinical sites) in the United States. The monitoring plan will include a pre-specified option to increase the planned sample size of 4700 women after interim evaluation by an independent Data Safety and Monitoring Board. R01 HD 064729 (Tita) 04/01/2010 ? 07/31/2015 NIH/NICHD Caesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) Trial A multicenter randomized trial to determine the efficacy and safety of a modified (extended-spectrum) antibiotic prophylaxis strategy at cesarean delivery to reduce surgical site infections. R01 AG 021927 (Marson) 07/01/2010 ? 06/30/2015 NIH/NIA Functional Change in Mild Cognitive Impairment (COINS) This R01 project investigates longitudinal change in higher order functional abilities in patients with MCI, and develops predictor models for clinical progression and conversion from MCI to dementia. No number assigned (Cutter) 01/01/2004 ? 12/31/2015 Consortium of MS Centers (CMSC) North American Research Consortium on Multiple Sclerosis (NARCOMS) The goals of this project are to facilitate a confidential way for patients to supply valuable information to researchers about their course of disease that may lead to more effective treatments and care. W81XWH-12-1-0155 (Korf) 05/15/2012 ? 05/14/2017 U.S. Department of Defense NEUTOFIBOMATOSIS CLINICAL CONSORTIUM AWARD This is a cooperative study group that is focusing on multiple trials in NF. The role of the operations center is both as the data center and the overall coordinating of the study group. U01NS45719 (Lublin) 06/01/2004 ? 11/30/2015 NIH/NINDS CombiRx Statistical and Data Management Center A Phase III, multi-center, double-blind, randomized study comparing the combined use of Interferon Beta-1a and Glatiramer Acetate to either agent alone in patients with relapsing remitting multiple sclerosis. 140305 (Greenberg) 09/01/2013 ? 08/31/2016 Patient Centered Outcomes Research Institute Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate (CAPTURE) U34 AR062891 (K. Saag) 04/15/2013 ? 03/31/2015 NIH/NIAMS Effectiveness of DiscontinuinG BisphosphonatEs Study (EDGE) Planning grant for a Pragmatic Clinical Trial (PCT), ?Effectiveness of DiscontinuinG bisphosphonatEs (EDGE) Study?, a ?real world? effectiveness trial of an initially estimated 4,100 patients randomized to continuation or discontinuation of prior alendronate therapy. P30DK079337 (Agarwal) 09/20/13 ? 07/31/18 NIH/NIDDK UAB/UCSD O?Brien Core Center for Acute Kidney Injury Research In summary, these cores and the outstanding cohort of investigators assembled for this center will provide unique expertise that is critical for innovative and productive research in AKI. With its Extended Research Base that includes both clinical and basic investigators, this O'Brien center will accelerate the translation of new investigative insights towards novel therapies for patients with AKI. RSTFD0000541263 (Cutter) 09/01/13 ? 08/31/17 Children?s Hospital (Boston) Early Biomarkers of Autism Spectrum Disorders in Infants with Tuberous Sclerosis MG Registry (Cutter) 01/01/14-present (annually) MGFA This is new registry (1.5 years old) that is a patient registry of Myasthenia Gravis Patients based solely on patient reported outcomes tracking their disease over time. CBD Trial (Cutter) 04/01/2014 ? 9/30/2015 State of Alabama The data management center for the effectiveness of cannabidiol (CBD) oil for the treatment of seizures and epilepsy.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Consortium of MS Centers (2) Myasthenia Gravis Foundation of America, grant for MG Registry

    Stock/Stock Options/Board of Directors Compensation:

    1. Pythagoras, Inc. Sub S Corporation - President. Cre8FIT - Sub S corporation - Daughter's exercise facility - investor and part owner.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Galderma Litigation (acne case) reviewed statistical data

  1. Mellen Center for Multiple Sclerosis (RJF), Cleveland Clinic, OH; and Department of Biostatistics (GC), University of Alabama at Birmingham School of Public Health.
  1. Correspondence to:
    FOXR{at}ccf.org
View Full Text

Article usage

Article usage: March 2016 to April 2023

AbstractFullPdfSource
Mar 20167826Highwire
Apr 20163131236Highwire
May 20168747Highwire
Jun 20167646Highwire
Jul 20162311Highwire
Aug 20163713Highwire
Sep 20163201Highwire
Oct 20163700Highwire
Nov 20165000Highwire
Dec 20164001Highwire
Jan 20174801Highwire
Feb 20172901Highwire
Mar 20173700Highwire
Apr 20171912Highwire
May 20171800Highwire
Jun 20171712Highwire
Jul 2017200Highwire
Aug 2017800Highwire
Sep 2017600Highwire
Oct 20171100Highwire
Nov 20171100Highwire
Dec 2017700Highwire
Jan 2018910Highwire
Feb 20182500Highwire
Mar 20181300Highwire
Apr 20181500Highwire
Apr 2018333pmc
May 20181800Highwire
Jun 2018900Highwire
Jun 2018245pmc
Jul 20181600Highwire
Aug 20181110Highwire
Aug 2018255pmc
Sep 2018700Highwire
Oct 2018800Highwire
Nov 20181900Highwire
Dec 20182000Highwire
Jan 20191100Highwire
Feb 2019800Highwire
Mar 2019900Highwire
Apr 20191101Highwire
May 2019900Highwire
Jun 2019900Highwire
Jul 2019200Highwire
Aug 2019100Highwire
Sep 20191200Highwire
Oct 20191501Highwire
Nov 20191201Highwire
Dec 20191300Highwire
Jan 20201000Highwire
Feb 20201000Highwire
Mar 20201101Highwire
Apr 20201201Highwire
May 20201121Highwire
Jun 2020400Highwire
Jul 2020810Highwire
Aug 2020400Highwire
Sep 2020400Highwire
Oct 20201300Highwire
Nov 20201000Highwire
Dec 20201200Highwire
Jan 20211010Highwire
Feb 20212100Highwire
Mar 2021900Highwire
Apr 2021500Highwire
May 20211000Highwire
Jun 2021900Highwire
Jul 2021900Highwire
Aug 20212400Highwire
Sep 2021701Highwire
Oct 20212200Highwire
Nov 2021200Highwire
Dec 20211200Highwire
Jan 20221200Highwire
Feb 20221600Highwire
Mar 20221200Highwire
Apr 20221400Highwire
May 20221400Highwire
Jun 2022700Highwire
Jul 2022101Highwire
Aug 2022400Highwire
Sep 20221800Highwire
Oct 20221300Highwire
Nov 20224100Highwire
Dec 20221100Highwire
Jan 20231800Highwire
Feb 20231200Highwire
Mar 2023400Highwire
Apr 2023800Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles